Cyclacel has contributed to many scientific advancements.
Identification of pharmacodynamic markers, sensitive target indications and potential combinations. Proc. Ann. Meeting AACR, 2017, Apr 1-5; Washington, D.C., Abstract 4178.
Therapeutic potential of novel PLK1 inhibitor CYC140 in esophageal cancer and acute leukemia. 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics; 2016 Nov 29–Dec 2; Munich, Germany. Abstract 355.
Parameters improving the therapeutic window of Compound 4, a potent and selective Polo-like kinase 1 inhibitor: in vitro studies. National Cancer Research Institute (NCRI) Cancer Conference 2012, Nov 4-7; Liverpool, UK. NCRI; Nov 2012. Abstract B15.
Potent and selective small molecule inhibitors of Polo-like kinase 1: Biological characterization. Proceedings of the 103rd Annual Meeting AACR; 2012, Mar 31-Apr 4; Chicago, Illinois. Philadelphia, PA: AACR; 2012. Abstract 2814.
Discovery, biological characterization and oral antitumor activity of polo-like kinase 1 (Plk1) selective small molecule inhibitors. Proceedings of the 101st Annual Meeting AACR; 2010, Apr 17-21; Washington, DC, Abstract 4435.